<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="149808">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01150032</url>
  </required_header>
  <id_info>
    <org_study_id>2009.588</org_study_id>
    <nct_id>NCT01150032</nct_id>
  </id_info>
  <brief_title>Bone Quality Lyon Orleans</brief_title>
  <acronym>QUALYOR</acronym>
  <official_title>Bone Quality and Improvement of Fracture Risk Prediction</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospices Civils de Lyon</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospices Civils de Lyon</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      QUALYOR is a prospective study on the predictive value for fragility fracture of various new
      techniques assessing bone quality, among postmenopausal women with low bone mass.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>September 2010</start_date>
  <completion_date type="Anticipated">February 2017</completion_date>
  <primary_completion_date type="Anticipated">February 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Fragility fracture</measure>
    <time_frame>4 years</time_frame>
    <description>Appearance of vertebral or non-vertebral fracture during the 4 years follow-up</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">1605</enrollment>
  <condition>Osteopenic Women</condition>
  <arm_group>
    <arm_group_label>Osteopenic women</arm_group_label>
    <description>Women with osteopenia: Bone Mineral Density T-score between -1.0 and -2.5 (for whom with clinical factor risk) or -3.0 (for whom without clinical factor risk)</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Bone quality complementary exams</intervention_name>
    <description>realisation of following exams to evaluate fracture risk in osteopenic women:
hip and wrist Dual energy X-ray Absorptiometry (DXA)
wrist and shin High-Resolution peripheral Quantitative Computed-Tomography(HR-pQCT)
hip Quantitative Computed Tomography (QCT)
High Resolution Digital X-Ray of calcaneum using BMA(tm) system
low-dose stereoradiography using EOS(tm) system (only for a sub-group of 60 voluntary subjects)</description>
    <arm_group_label>Osteopenic women</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Frozen plasma: for later genetic studies Frozen serum: for later studies on new potential
      marker of bone remodelling
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        50 years old or older women with lowered Bone Mineral Density
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  50 or older women

          -  post-menopausal since at least one year

          -  with osteopenia (T-score between -1.0 and -2.5 (with clinical factor risk) or -3.0
             (without clinical factor risk)

        Exclusion Criteria:

          -  corticosteroid therapy &gt; 3 months, at least 7.5mg/day equivalent prednisolon (stopped
             since at least 1 year)

          -  osteoporosis treatment antecedent

          -  fragility fracture antecedent

          -  on going post-menopausal hormonal treatment

          -  clinical signs of hepatic, cardiac or respiratory insufficiency, diseases possibly
             affecting bone metabolism

          -  life expectancy &lt; 4 years, mental or serious illness
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Roland CHAPURLAT, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospices Civils de Lyon</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospices Civils de Lyon</name>
      <address>
        <city>Lyon</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier d'Orléans</name>
      <address>
        <city>Orléans</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>December 2010</verification_date>
  <lastchanged_date>January 17, 2013</lastchanged_date>
  <firstreceived_date>June 23, 2010</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Osteoporosis</keyword>
  <keyword>Fracture</keyword>
  <keyword>Bone microarchitecture</keyword>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
